Skip to content

CG Oncology CGON Short- term Investments

Short- term Investments at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
Gilead Sciences logo
Gilead SciencesGILD
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Tango Therapeutics logo
Tango TherapeuticsTNGX
Exelixis logo
ExelixisEXEL
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%
Enterprise value$5.36B+212%
P/S1,062.4×-1,596×

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's short- term investments?
CG Oncology (CGON) reported short- term investments of $1.04B in Q1 2026.
How has CG Oncology's short- term investments changed year-over-year?
CG Oncology's short- term investments increased by 61.1% year-over-year, from $646.96M to $1.04B.
What is the long-term trend for CG Oncology's short- term investments?
Over 2 years (2023 to 2025), CG Oncology's short- term investments has grown at a 98.9% compound annual growth rate (CAGR), from $179.41M to $709.67M.